Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome

• Published in: Frontiers in immunology Vol. 10; p. 460
• Main Authors: Manganelli, Valeria, Truglia, Simona, Capozzi, Antonella, Alessandri, Cristiano, Riitano, Gloria, Spinelli, Francesca Romana, Ceccarelli, Fulvia, Mancuso, Silvia, Garofalo, Tina, Longo, Agostina, Valesini, Guido, Sorice, Maurizio, Conti, Fabrizio, Misasi, Roberta
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.03.2019
• Subjects: antiphospholipid syndrome; HMGB1; Immunology; recurrent abortion; sRAGE; thrombosis; antiphospholipid syndrome; recurrent abortion; sRAGE; thrombosis; HMGB1
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.00460

Antiphospholipid antibody syndrome (APS) is a systemic autoimmune disease characterized by arterial and/or venous thrombosis, pregnancy morbidity in the presence of circulating "anti-phospholipid antibodies" (aPL). One of the main target antigens of aPL is β -glycoprotein I (β -GPI). APS may occur as a primary syndrome or associated with Systemic Lupus Erythematosus (SLE). High Mobility Group Box 1 (HMGB1) is a nuclear non-histone protein which is secreted from different type of cells during activation and/or cell death and may act as a proinflammatory mediator through ligation to its receptors, including RAGE. There is accumulating evidence that HMGB1 contributes to the pathogenesis of inflammatory and autoimmune diseases, especially SLE. In a previous study we demonstrated increased serum levels of HMGB1 in both primary and secondary APS patients. In this work we analyzed: (i) whether anti-β -GPI antibodies from APS patients may induce both a HMGB1 cellular relocation by activation of its putative receptor RAGE in platelets and monocytes and, (ii) , serum levels of HMGB1/soluble RAGE (sRAGE) in APS patients and their possible correlation with clinical manifestations. Platelets and monocytes from healthy donors were incubated with affinity purified anti-β -GPI antibodies. HMGB1 and RAGE expression were analyzed by Western Blot. Sera from 60 consecutive APS patients (primary or secondary), diagnosed according to the Sydney Classification Criteria, were enrolled. As a control, 30 matched healthy subjects were studied. Serum levels of HMGB1 and sRAGE were analyzed by Western Blot. results showed that anti-β -GPI antibodies were able to induce RAGE activation and HMGB1 cellular relocation in both monocytes and platelets. HMGB1 and sRAGE serum levels were significantly increased in APS patients in comparison with healthy subjects ( <0.0001). Interestingly, APS patients with spontaneous recurrent abortion showed significantly higher levels of sRAGE; moreover, in APS patients a direct correlation between serum levels of HMGB1 and disease duration was detected. Our observations suggest that anti-β -GPI antibodies may trigger RAGE activation and HMGB1 cellular relocation during APS. Monitoring these molecules serum levels may represent an useful tool to evaluate the pathogenesis and risk stratification of clinical manifestations in APS.